



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#8/A
mp
9/6/02

Applicant: William E. KLUNK *et al.*

Title: THIOFLAVIN DERIVATIVES FOR
USE IN ANTEMORTEM
DIAGNOSIS OF ALZHEIMER'S
DISEASE AND IN VIVO IMAGING
AND PREVENTION OF AMYLOID
DEPOSITION

RECEIVED

AUG 28 2002

Appl. No.: 09/935,767

TECH CENTER 1600/2900

Filing Date: 08/24/2001

Examiner: D. L. Jones

Art Unit: 1645

AMENDMENT AND RESPONSE TO RESTRICTION REQUIREMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the restriction requirement set forth in an Office Action mailed July 23, 2002, Applicants hereby elect the Group XIII claims, relating compounds comprised of Structure D, wherein $Z = S$. Claims 1-43 also have been cancelled in favor of claims 44-130, which are added to simplify prosecution and to cover Structure D compounds wherein $Z = S$, per the original claims. Support for the new claims can be found throughout the specification, including in the original claims.

The action additionally communicates a requirement for election of species. In response, applicants elect the species of compounds under Structure D wherein $R^1 = H$, $R^2 = CH_3$, $R^3 - R^7 = H$, $R^8 = OR'$ (wherein $R' = H$), $R^9 - R^{10} = H$, $Y = NR^1R^2$, and $Z = S$. Claims 44, 57-60, 63-75, 77, 84, 106, 107, 111, 114, and 117-124 are drawn to the elected species; claims 45, 76, 90, and 125-130 cover the elected specie when at least one carbon is a radioisotope.

08/26/2002 CCHAU1 00000115 190741 09935767

01 FC:103	1800.00 OP
02 FC:102	840.00 OP
03 FC:104	10.00 CH 270.00 OP